Accuray Incorporated (NASDAQ:ARAY) Shares Bought by Wells Fargo & Company MN

Wells Fargo & Company MN increased its stake in Accuray Incorporated (NASDAQ:ARAY) by 37.7% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 260,071 shares of the medical equipment provider’s stock after acquiring an additional 71,198 shares during the period. Wells Fargo & Company MN owned approximately 0.25% of Accuray worth $515,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the stock. Heartland Advisors Inc. raised its holdings in Accuray by 14.1% in the fourth quarter. Heartland Advisors Inc. now owns 3,824,750 shares of the medical equipment provider’s stock valued at $7,573,000 after buying an additional 472,800 shares during the period. JPMorgan Chase & Co. boosted its position in Accuray by 482.4% in the 4th quarter. JPMorgan Chase & Co. now owns 242,713 shares of the medical equipment provider’s stock valued at $481,000 after buying an additional 201,037 shares during the last quarter. Virtu Financial LLC acquired a new stake in Accuray during the 3rd quarter valued at approximately $244,000. Barclays PLC grew its position in shares of Accuray by 97.9% during the third quarter. Barclays PLC now owns 210,819 shares of the medical equipment provider’s stock worth $380,000 after buying an additional 104,310 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its position in shares of Accuray by 28.7% in the 4th quarter. Assenagon Asset Management S.A. now owns 212,330 shares of the medical equipment provider’s stock worth $420,000 after purchasing an additional 47,331 shares during the last quarter. 64.08% of the stock is currently owned by hedge funds and other institutional investors.

Accuray Price Performance

Shares of NASDAQ ARAY opened at $1.37 on Friday. The business’s fifty day moving average price is $1.70 and its two-hundred day moving average price is $1.93. The firm has a market capitalization of $140.36 million, a PE ratio of -27.30 and a beta of 1.30. The company has a debt-to-equity ratio of 3.51, a current ratio of 1.62 and a quick ratio of 0.88. Accuray Incorporated has a 1-year low of $1.34 and a 1-year high of $2.95.

Accuray (NASDAQ:ARAY) last posted its earnings results on Wednesday, April 30th. The medical equipment provider reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.05) by $0.04. The firm had revenue of $113.24 million during the quarter, compared to analysts’ expectations of $101.53 million. Accuray had a negative net margin of 0.96% and a negative return on equity of 9.75%. On average, research analysts expect that Accuray Incorporated will post 0.01 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised Accuray from a “hold” rating to a “buy” rating in a research report on Friday, April 11th.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.